Glenmark launches Winlevi across key European markets
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Subscribe To Our Newsletter & Stay Updated